About: Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series
Creator	Moore, Peter Barrett, Christopher Moore, B Hajizadeh, Negin Hunter, \| Mcintyre, Robert Michael, \| Moore, Ernest Veress, Livia Wang, Janice Yaffe, B
Source	Medline; PMC
abstract	A prothrombotic coagulopathy is commonly found in critically ill COVID‐19 patients with acute respiratory distress syndrome (ARDS). A unique feature of COVID‐19 respiratory failure is a relatively preserved lung compliance and high Alveolar‐arterial oxygen gradient, with pathology reports consistently demonstrating diffuse pulmonary microthrombi on autopsy, all consistent with a vascular occlusive etiology of respiratory failure rather than the more classic findings of low‐compliance in ARDS. The COVID‐19 pandemic is overwhelming the world’s medical care capacity with unprecedented needs for mechanical ventilators and high rates of mortality once patients progress to needing mechanical ventilation, and in many environments including in parts of the United States the medical capacity is being exhausted. Fibrinolytic therapy has previously been used in a Phase 1 clinical trial that led to reduced mortality and marked improvements in oxygenation. Here we report a series of three patients with severe COVID‐19 respiratory failure who were treated with tissue plasminogen activator. All three patients had a temporally related improvement in their respiratory status, with one of them being a durable response.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.1111/jth.14828
bibo:pmid	32267998
has license	no-cc
sha1sum (hex)	9199a312f9a77bc456db072da5b5583715ed4d6e
schema:url	https://doi.org/10.1111/jth.14828
resource representing a document's title	Tissue plasminogen activator (tPA) treatment for COVID‐19 associated acute respiratory distress syndrome (ARDS): A case series
has PubMed Central identifier	PMC7262152
has PubMed identifier	32267998
schema:publication	J Thromb Haemost
resource representing a document's body	covid:9199a312f9a77bc456db072da5b5583715ed4d6e#body_text
is schema:about of	named entity 'critically ill' named entity 'COVID-19' named entity 'PATIENTS' named entity 'COVID-19' named entity 'high' named entity 'COVID-19' named entity 'hypotension' named entity 'HD 2' named entity 'critically ill' named entity 'tPA' named entity 'prone position' named entity 'infusion' named entity 'heparin' named entity 'oxygen' named entity 'mm Hg' named entity 'FiO2' named entity 'emergency department' named entity 'fever' named entity 'DIC' named entity 'microthrombi' named entity 'D-dimer' named entity 'CRRT' named entity 'D-dimer' named entity 'cough' named entity 'heparin' named entity 'coagulopathy' named entity 'lung compliance' named entity 'respiratory failure' named entity 'critically ill' named entity 'COVID' named entity 'acute respiratory distress syndrome' named entity 'Tissue plasminogen activator' named entity 'Phase 1 clinical trial' named entity 'medical history' named entity 'mechanically ventilated' named entity 'fibrinolytic therapy' named entity 'arrhythmia' named entity 'anticoagulation' named entity 'COVID-19 pandemic' named entity 'tPA' named entity 'fibrin' named entity 'vasopressor' named entity 'tPA' named entity 'ARDS' named entity 'fibrinogen' named entity 'mm Hg' named entity 'multiple organ failure' named entity 'Computed tomography' named entity 'ARDS' named entity 'venous thromboembolism' named entity 'tPA' named entity 'thrombosis' named entity 'tPA' named entity 'tPA' named entity 'CRRT' named entity 'vasopressin' named entity 'intubated' named entity 'respiratory failure' named entity 'heart rate' named entity 'case report' named entity 'SpO2' named entity 'infusion' named entity 'tPA' named entity 'tissue plasminogen activator' named entity 'blood pressure' named entity 'intravenous administration' named entity 'infusion' named entity 'ARDS' named entity 'thrombosis' named entity 'infusion' named entity 'fatigue'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software